Table A1.
The list of pathways that play key role in asthma pathogenesis, as evident from the biomarkers identified by genomics, proteomics and epigenomics approaches.
| Name of the pathway | Total entities | Expanded of entities | Overlap | Percent overlap | Overlapping entities | p-value | (−logP) |
|---|---|---|---|---|---|---|---|
| Adipocytokine signaling | 52 | 780 | 13 | 1 | ACSL3, IL13, IL9, IL4, IL2, IL10, IFNA1, SOCS1, PON1, APOB, SOCS3, SCD, NR1D1 | 0.001809 | 2.742605 |
| ROS metabolism | 43 | 74 | 3 | 4 | PRDX6, SOD1, CYBB | 0.004493 | 2.347436 |
| ActivinR -> SMAD2/3 signaling | 23 | 23 | 2 | 8 | INHBA, INHA | 0.010913 | 1.962064 |
| Urea cycle and arginine metabolism | 86 | 110 | 3 | 2 | NOS2A, ARG1, ARG2 | 0.013536 | 1.868503 |
| Translation control | 86 | 984 | 13 | 1 | CCL11, EGFR, IL13, IL9, IL4, IL2, IL10, CCL21, IFNA1, SOCS1, VEGFC, SOCS3, GNB2 | 0.013549 | 1.86809 |
| ActivinR/BMPR -> SMAD1/5/9 signaling | 27 | 27 | 2 | 7 | INHBA, INHA | 0.014876 | 1.827505 |
| Apoptosis regulation | 69 | 613 | 9 | 1 | IL13, IL9, IL4, TGFB1, IL2, IL10, IFNA1, INHBA, INHA | 0.022869 | 1.640747 |
| Mast cell activation | 64 | 529 | 8 | 1 | PTGS2, IL13, IL9, IL4, IL2, IL10, IFNA1, ALOX15 | 0.027347 | 1.563092 |
| Skeletal myogenesis control | 70 | 569 | 8 | 1 | EGFR, TGFB1, SOCS1, INHBA, CYBB, VEGFC, INHA, SOCS3 | 0.039923 | 1.39878 |
| NK Cell Activation | 59 | 523 | 7 | 1 | IL13, IL9, IL4, IL2, IL10, IFNA1, TYROBP | 0.067085 | 1.173375 |
| EDG2 -> ELK-SRF signaling | 33 | 78 | 2 | 2 | EGFR, GNB2 | 0.102033 | 0.991259 |
| T cell activation | 81 | 1100 | 11 | 1 | SGPP1, PTGS2, IL13, IL9, IL4, IL2, IL10, CTLA4, IFNA1, ALOX15, CNN1 | 0.129288 | 0.888442 |
| GFR -> FOXO3A signaling | 7 | 94 | 2 | 2 | EGFR, VEGFC | 0.138723 | 0.857852 |
| DopamineR2 -> AP-1/CREB/ELK-SRF signaling | 47 | 95 | 2 | 2 | EGFR, GNB2 | 0.141106 | 0.850455 |
| CholinergicRm -> CREB/ELK-SRF signaling | 41 | 107 | 2 | 1 | EGFR, GNB2 | 0.170351 | 0.768655 |
| GRM1/5 -> CREB signaling | 39 | 110 | 2 | 1 | EGFR, GNB2 | 0.177823 | 0.750012 |
| Melanogenesis | 51 | 682 | 7 | 1 | INMT, CCL11, EGFR, CCL21, PRDX6, VEGFC, GNB2 | 0.190612 | 0.71985 |
| Adherens junction regulation | 41 | 692 | 7 | 1 | EGFR, TGFB1, INHBA, VEGFC, CDH11, INHA, DSP | 0.20054 | 0.697799 |
| GFR -> NCOR2 signaling | 27 | 130 | 2 | 1 | EGFR, VEGFC | 0.228743 | 0.640652 |
| GFR -> AP-1/CREB/CREBBP/ELK-SRF/MYC signaling | 50 | 156 | 2 | 1 | EGFR, VEGFC | 0.296227 | 0.528375 |
The data was generated using Pathway studio 7.1, Ariadane Genomics, Rockville, MD, USA. The column names are: Name of the pathway; Total entities; expanded entities; overlap; percent overlap; overlapping entities; p-value and −log10 p-value.